1. Home
  2. ABLV vs ATNM Comparison

ABLV vs ATNM Comparison

Compare ABLV & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

N/A

Current Price

$0.69

Market Cap

36.1M

Sector

N/A

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.11

Market Cap

36.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
ATNM
Founded
2015
2000
Country
China
United States
Employees
89
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.1M
36.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ABLV
ATNM
Price
$0.69
$1.11
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
5.2K
104.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.60
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$1.02
52 Week High
$1.77
$1.95

Technical Indicators

Market Signals
Indicator
ABLV
ATNM
Relative Strength Index (RSI) 39.23 43.37
Support Level $0.60 $1.02
Resistance Level $0.97 $1.25
Average True Range (ATR) 0.03 0.07
MACD -0.01 0.01
Stochastic Oscillator 24.24 38.74

Price Performance

Historical Comparison
ABLV
ATNM

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: